Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 4.82 · gapped above the open, then crossed back over prior close. High/low 4.89 at 9:45 am ET, 4.79 at 12:00 pm ET.
Aquestive Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of AQST revenue | Skew |
|---|---|---|---|
| INDVIndivior | 2.62% | 73.00% | 28× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Indivior accounted for approximately 73% and 62% of our revenues for 2025 and 2024, respectively, and we believe in the future will continue to account for a substantial part of our revenues.”
$33M relationship28× more of AQST’s book than INDV’s
basisAQST fy2025 · closed 2025-12 $45MINDV fy2025 · closed 2025-12 $1.2B
FILING10-K0001398733-26-000018cik 0001398733
“We manufacture based on receipt of purchase orders from our licensees, and our licensees have an obligation to accept these orders once quality assurance validates the quality of the manufactured product with agreed upon technical specifications.”
FILING10-K0001398733-26-000018cik 0001398733
“On August 13, 2025, we entered into a purchase and sale agreement with funds managed by RTW Investments LP ("RTW" or "Purchaser").”
FILING10-K0001398733-26-000018cik 0001398733
“Under the terms of the Monetization Agreement, we sold to Marathon all of our contractual rights to receive royalties and milestone payments due under the Sunovion License Agreement related to Sunovion's apomorphine product, KYNMOBI, an apomorphine film therapy for the treatment of off episodes in Parkinson's disease patients, which received approval from the FDA on May 21, 2020.”
FILING10-K0001398733-26-000018cik 0001398733
“Aquestive is the exclusive sole manufacturer and supplier of Sympazan for Assertio and will receive manufacturing fees from Assertio for the product through the expiration of such License Agreement.”
FILING10-K0001398733-26-000018cik 0001398733
“On October 26, 2022, we entered into a License Agreement with Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc., pursuant to which we granted an exclusive, worldwide license of its intellectual property for Sympazan to Assertio during the term of that agreement for an upfront payment of $9,000.”
FILING10-K0001398733-26-000018cik 0001398733
“Aquestive was the exclusive sole manufacturer and supplier for Exservan in China.”
FILING10-K0001398733-26-000018cik 0001398733
“On November 3, 2020, we entered into the Monetization Agreement with Marathon.”
FILING10-K0001398733-26-000018cik 0001398733
“Under the terms of the MTPA license agreement, Aquestive was the exclusive manufacturer and supplier of Exservan for MTPA in the United States.”
FILING10-K0001398733-26-000018cik 0001398733
“We licensed commercial rights for this product to Hypera in Brazil (which Hypera markets as Ondif).”
FILING10-K0001398733-26-000018cik 0001398733
“We entered into the Pharmanovia Agreement with Pharmanovia, effective as of September 26, 2022, pursuant to which we granted Pharmanovia an exclusive license to certain of our intellectual property to develop and commercialize Libervant for the treatment of prolonged or acute, convulsive seizures in all ages in certain countries of the Territory, as defined in the Pharmanovia Agreement, during the term of the Pharmanovia Agreement.”
FILING10-K0001398733-26-000018cik 0001398733
“We licensed our intellectual property to Cynapsus Therapeutics, Inc., a company that was acquired by Sunovion for the commercialization of KYNMOBI under the Sunovion License Agreement.”
FILING10-K0001398733-26-000018cik 0001398733
“During the second quarter of 2025, Aquestive earned a $500 milestone payment in connection with the sale of Emylif pursuant to the terms of the license agreement with Zambon.”
FILING10-K0001398733-26-000018cik 0001398733
“Pursuant to the terms of the March 2012 agreement with Zevra, we began to receive milestone and royalty revenues for Azstarys.”
FILING10-K0001398733-26-000018cik 0001398733
Watchlist prices, news filtered to it, and its next report on your desk.
Aquestive Therapeutics, Inc. has 0 disclosed suppliers and 14 disclosed customers. Each one is named in an SEC filing, either Aquestive Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a supplier of Aquestive Therapeutics, Inc.. Suppliers appear here when Aquestive Therapeutics, Inc. names them in its own annual report, or when a company names Aquestive Therapeutics, Inc. as a customer in theirs.
AQST (Aquestive Therapeutics, Inc.) has 0 disclosed suppliers and 14 disclosed customers, strongest disclosure first.
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: INDV −0.76%, in healthcare.